Alan Hruza

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index2.8kcitations71works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(32), Synthesis and biological activity(15), Cancer-related Molecular Pathways(9), Computational Drug Discovery Methods(8), Microtubule and mitosis dynamics(7)

Publications71 total

<i>N</i> -Alkyl and <i>N</i> -Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors
ACS Medicinal Chemistry Letters·2026
The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors
ACS Pharmacology & Translational Science·2025Open Access
Ketoreductase Engineering for a Chemoenzymatic Fluorination and Dynamic Kinetic Reduction Cascade
ACS Catalysis·2025· 4 cited
Ketoreductase Engineering for a Chemoenzymatic Fluorination and Dynamic Kinetic Reduction Cascade
2025
Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat <i>Acinetobacter baumannii</i>: From Screening Impurity to <i>In Vivo</i> Efficacy
Journal of Medicinal Chemistry·2024· 5 cited
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S2 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Table S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Information Figure S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Data from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Priya Dayananth(14), Ahmed A. Samatar(14), Erick J. Morris(10), Sharda Jha(10), Clifford R. Restaino(10), Paul T. Kirschmeier(10), Lata Jayaraman(10), Leigh Zawel(10), Stephen E. Fawell(10), Ronald J. Doll(10), William T. Windsor(9), Thierry Fischmann(9), Paul Reichert(9), My Sam Mansueto(9), Gerald W. Shipps(8), Gottfried K. Schroeder(8), Jaren Arbanas(8), Daniel R. McMasters(8), Nathaniel L. Elsen(8), Anthony Mannarino(8)